• Biotronik (Lake Oswego, Oregon) reported the release of the Stratos LV cardiac resynchronization therapy pacemaker (CRT-P). Stratos LV is a CRT pacemaker — a device which provides low-voltage stimulation for resynchronization therapy, but not defibrillation. CRT devices are indicated for certain types of heart failure patients and may improve the pumping action of the heart by helping to synchronize the heart's lower chambers (the ventricles). Stratos LV offers a feature to help assure that resynchronization therapy is delivered continuously with RVsense Triggering. RVsense Triggering helps maintain resynchronization by forcing the pacemaker to pace the left ventricle whenever there is activity in the right ventricle (whether it is a paced event or the heart beats on its own). This assures that there will be no "one-sided" cardiac activity, and may help to preserve ventricular ejection fraction (a standard measure of the heart's ability to pump blood efficiently), reduce symptoms of heart failure, and synchronize ventricular intrinsic contraction within 2.5 ms of a sensed or paced event in the right ventricle. Biotronik is a cardiovascular medical device company.
  • Medtronic (Minneapolis) reported that data from a multi-center, prospective, randomized, single-blinded, controlled investigational study using its neurostimulation system to stimulate the occipital nerves as a potential approach to treating medically refractory chronic migraines will be presented during a late-breaking session at the annual scientific meeting of the American Headache Society. In the study, thin lead wires were placed under the skin near the occipital nerves, which arise from the spinal cord and branch out across the back of the head carrying sensory signals from that region to the brain. The leads were connected to an implanted Medtronic neurostimulator that delivered controlled electrical pulses to the occipital nerves. Patients were randomized to three groups to receive: either a neurostimulator and have the ability to control the level of stimulation; or a neurostimulator as part of a device control group; or only standard medical management instead of an ONS implant. A positive response was defined as at least a 50% reduction in the number of headache days in a month, or a reduction in the pain intensity of at least three points on a standard 0-10 pain scale.
  • Neoprobe (Dublin, Ohio) said it has introduced an enhanced gamma detection control unit, the Neoprobe GDS (Model 2300), in connection with the company's marketing partner, Ethicon Endo-Surgery. The Neoprobe GDS control unit contains internal circuitry that enables it to communicate with Neoprobe's other wireless probes without the necessity of an external adapter. Neoprobe's wireless probes are available with either straight or angled tips and can also be used with all previous models of the company's neo2000 control unit (Models 2000, 2100 and 2200) using an external serial port adapter. Neoprobe makes oncology and cardiovascular surgical and diagnostic products.
  • Smiths Detection (Edgewood, Maryland) reported the launch of SmartBio Sensor (SBS), a real-time detector for biological agents or airborne toxins. SBS provides a visual or audio alarm when a bio-threat is detected and classifies the agent by threat category. SBS takes continuous samples of the air, trapping bio-agents on to coupons. The onboard computer then classifies the threat and triggers the alarm. Bio-agents are retained for confirmatory analysis and archiving. SBS also has an onboard particle counter to maintain a low response to natural chemical and biological interferents in the air. Smiths Detection is part of the Smiths Group. It provides integrated security solutions for customers in civil and military markets.
  • Tri-Isthmus Group (TIGroup; Beverly Hills, California) said that patients and physicians in the Oklahoma communities of Stroud, Chickasha and Anadarko will soon be able to access the latest diagnostic imaging technology. TIGroup's diagnostic CTs enable physicians to detect and treat life-threatening illnesses such as heart disease, cancer, stroke and lung disease at an earlier stage. Patients benefit due to the greater number of treatment options available after early stage detection and quicker scan times. These new CT systems replace single-slice CT units at both facilities, which often required patient scan times of more than 20 minutes. The new scanners reduce patient exposure to radiation, which supports TIGroup's commitment to patient safety. Tri-Isthmus Group provides financial solutions to the healthcare industry.
  • Vistakon (Jacksonville, Florida) reported the introduction of Acuvue OASYS brand contact lenses for astigmatism. The OASYS for Astigmatism combines the accelerated stabilization design (ASD) technology of Acuvue Advance brand contact lenses for astigmatism, with senofilcon A, the silicone hydrogel material of Acuvue OASYS lenses. The lens also features Hydraclear Plus, the improved formulation of the Hydraclear technology that combines high performance base materials with a moisture-rich wetting agent. The Vistakon division of Johnson & Johnson Vision Care specializes in disposable contact lenses.